JP2021519297A - Ｔｒｋキナーゼ阻害剤としての大環状化合物 - Google Patents

Ｔｒｋキナーゼ阻害剤としての大環状化合物 Download PDF

Info

Publication number
JP2021519297A
JP2021519297A JP2020551805A JP2020551805A JP2021519297A JP 2021519297 A JP2021519297 A JP 2021519297A JP 2020551805 A JP2020551805 A JP 2020551805A JP 2020551805 A JP2020551805 A JP 2020551805A JP 2021519297 A JP2021519297 A JP 2021519297A
Authority
JP
Japan
Prior art keywords
alkyl
cycloalkyl
independently selected
heterocyclyl
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020551805A
Other languages
English (en)
Japanese (ja)
Inventor
フアジエ ジャン，
フアジエ ジャン，
チーホン リウ，
チーホン リウ，
チェンシー ホー，
チェンシー ホー，
ウェイポン ジャン，
ウェイポン ジャン，
ルイ タン，
ルイ タン，
ビン リウ，
ビン リウ，
ホン フー，
ホン フー，
ハオハン タン，
ハオハン タン，
リジュン ヤン，
リジュン ヤン，
ホンビン リウ，
ホンビン リウ，
ユンリン ワン，
ユンリン ワン，
ユーウェイ ガオ，
ユーウェイ ガオ，
ゾンヤオ ゾウ，
ゾンヤオ ゾウ，
ヤンシン リウ，
ヤンシン リウ，
シュウ リン，
シュウ リン，
トンシュアン リ，
トンシュアン リ，
シンドン ジャオ，
シンドン ジャオ，
ウェイボー ワン，
ウェイボー ワン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fochon Pharmaceuticals Ltd
Original Assignee
Fochon Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fochon Pharmaceuticals Ltd filed Critical Fochon Pharmaceuticals Ltd
Publication of JP2021519297A publication Critical patent/JP2021519297A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2020551805A 2018-03-28 2019-03-27 Ｔｒｋキナーゼ阻害剤としての大環状化合物 Pending JP2021519297A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862648999P 2018-03-28 2018-03-28
US62/648,999 2018-03-28
US201862674755P 2018-05-22 2018-05-22
US62/674,755 2018-05-22
US201862684535P 2018-06-13 2018-06-13
US62/684,535 2018-06-13
US201962800496P 2019-02-02 2019-02-02
US62/800,496 2019-02-02
PCT/CN2019/079909 WO2019184955A1 (fr) 2018-03-28 2019-03-27 Composés macrocycliques en tant qu'inhibiteurs de kinases trk

Publications (1)

Publication Number Publication Date
JP2021519297A true JP2021519297A (ja) 2021-08-10

Family

ID=68060871

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020551805A Pending JP2021519297A (ja) 2018-03-28 2019-03-27 Ｔｒｋキナーゼ阻害剤としての大環状化合物

Country Status (10)

Country Link
US (1) US11555042B2 (fr)
EP (1) EP3774812A4 (fr)
JP (1) JP2021519297A (fr)
KR (1) KR20200141041A (fr)
CN (1) CN111971287B (fr)
AU (1) AU2019241260B2 (fr)
BR (1) BR112020019399A2 (fr)
CA (1) CA3093140A1 (fr)
MX (1) MX2020010116A (fr)
WO (1) WO2019184955A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021519828A (ja) * 2018-04-25 2021-08-12 プライムジーン（ベイジン）カンパニー リミテッド ジアリール大員環化合物、医薬組成物及びその用途

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6986789B2 (ja) 2017-11-10 2021-12-22 エンジェクス ファーマシューティカル インコーポレイテッド 化合物、その薬学的に許容される塩、化合物の使用および医薬組成物
CN113773335A (zh) * 2019-06-21 2021-12-10 成都海博为药业有限公司 一种作为蛋白质激酶抑制剂的化合物及其制备方法和用途
US20230219978A1 (en) * 2020-06-04 2023-07-13 Scinnohub Pharmaceutical Co., Ltd Compound having macrocyclic structure and use thereof
WO2021259309A1 (fr) * 2020-06-24 2021-12-30 广州市恒诺康医药科技有限公司 Agoniste du récepteur glp-1, composition pharmaceutique et utilisation associées
CN111875620B (zh) * 2020-09-28 2020-12-11 上海美迪西生物医药股份有限公司 吡唑并嘧啶类大环衍生物及其应用
CN113582994B (zh) * 2021-09-28 2022-02-11 北京鑫开元医药科技有限公司 具有trk激酶抑制活性的化合物、制备方法、组合物及其用途

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013530142A (ja) * 2010-05-20 2013-07-25 アレイ バイオファーマ、インコーポレイテッド Ｔｒｋキナーゼ阻害剤としてのマクロ環化合物
WO2017004342A1 (fr) * 2015-07-02 2017-01-05 Tp Therapeutics, Inc. Macrocycles de diaryle chiraux à utiliser en tant que modulateurs de protéines kinases
WO2017015367A1 (fr) * 2015-07-21 2017-01-26 Tp Therapeutics, Inc. Macrocycles diaryles chiraux et leurs utilisations
JP2017503867A (ja) * 2014-01-24 2017-02-02 ティーピー・セラピューティクス・インコーポレイテッドＴｐ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． タンパク質キナーゼのモジュレータとしてのジアリール大環状化合物
WO2017035354A1 (fr) * 2015-08-26 2017-03-02 Blueprint Medicines Corporation Composés et compositions utiles pour traiter des troubles associés au gène ntrk
WO2017075107A1 (fr) * 2015-10-26 2017-05-04 Nanda Nisha Mutations ponctuelles dans le cancer résistant aux inhibiteurs de trk et méthodes associées

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015011286A1 (fr) 2013-07-26 2015-01-29 Essilor International (Compagnie Generale D'optique) Présentoir de lunettes sur prescription en libre service
CN104672250B (zh) * 2013-11-29 2017-11-07 广东东阳光药业有限公司 取代的杂芳基化合物及其组合物和用途
HUE054784T2 (hu) * 2014-05-23 2021-09-28 Hoffmann La Roche 5-klór-2-difluor-metoxifenil-pirazolopirimidin vegyületek, amelyek JAK-gátlók
EP3226688B1 (fr) * 2014-12-05 2020-07-01 Merck Sharp & Dohme Corp. Composés tricycliques servant d'inhibiteurs d'enzymes idh mutantes
CN108779117B (zh) * 2015-12-27 2021-08-31 重庆复创医药研究有限公司 一类激酶抑制剂
CN109071512A (zh) * 2016-02-03 2018-12-21 重庆复创医药研究有限公司 作为激酶抑制剂的含磷化合物
EP3490564A4 (fr) 2016-07-28 2020-02-26 Turning Point Therapeutics, Inc. Inhibiteurs macrocycliques de kinases
CN109516999B (zh) * 2017-11-01 2021-08-17 郑州泰基鸿诺医药股份有限公司 用作蛋白质激酶调节剂的化合物及其应用

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013530142A (ja) * 2010-05-20 2013-07-25 アレイ バイオファーマ、インコーポレイテッド Ｔｒｋキナーゼ阻害剤としてのマクロ環化合物
JP2017503867A (ja) * 2014-01-24 2017-02-02 ティーピー・セラピューティクス・インコーポレイテッドＴｐ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． タンパク質キナーゼのモジュレータとしてのジアリール大環状化合物
WO2017004342A1 (fr) * 2015-07-02 2017-01-05 Tp Therapeutics, Inc. Macrocycles de diaryle chiraux à utiliser en tant que modulateurs de protéines kinases
WO2017015367A1 (fr) * 2015-07-21 2017-01-26 Tp Therapeutics, Inc. Macrocycles diaryles chiraux et leurs utilisations
WO2017035354A1 (fr) * 2015-08-26 2017-03-02 Blueprint Medicines Corporation Composés et compositions utiles pour traiter des troubles associés au gène ntrk
WO2017075107A1 (fr) * 2015-10-26 2017-05-04 Nanda Nisha Mutations ponctuelles dans le cancer résistant aux inhibiteurs de trk et méthodes associées

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021519828A (ja) * 2018-04-25 2021-08-12 プライムジーン（ベイジン）カンパニー リミテッド ジアリール大員環化合物、医薬組成物及びその用途
JP7128345B2 (ja) 2018-04-25 2022-08-30 プライムジーン（ベイジン）カンパニー リミテッド ジアリール大員環化合物、医薬組成物及びその用途

Also Published As

Publication number Publication date
CN111971287A (zh) 2020-11-20
EP3774812A4 (fr) 2021-12-15
US11555042B2 (en) 2023-01-17
KR20200141041A (ko) 2020-12-17
WO2019184955A1 (fr) 2019-10-03
EP3774812A1 (fr) 2021-02-17
CA3093140A1 (fr) 2019-10-03
AU2019241260A1 (en) 2020-10-01
MX2020010116A (es) 2020-11-06
RU2020133631A3 (fr) 2022-05-04
US20210139506A1 (en) 2021-05-13
RU2020133631A (ru) 2022-05-04
CN111971287B (zh) 2023-06-02
AU2019241260B2 (en) 2022-06-16
BR112020019399A2 (pt) 2021-01-05

Similar Documents

Publication Publication Date Title
JP2021519297A (ja) Ｔｒｋキナーゼ阻害剤としての大環状化合物
JP7294677B2 (ja) ＴＲＫキナーゼ阻害剤としての置換（２－アザビシクロ［３．１．０］ヘキサン－２－イル）ピラゾロ［１，５－ａ］ピリミジン化合物及び置換（２－アザビシクロ［３．１．０］ヘキサン－２－イル）イミダゾ［１，２－ｂ］ピリダジン化合物
TWI736578B (zh) 6-5元稠合唑環衍生物及其藥物組合物，以及作為藥物的應用
KR20220016090A (ko) 단백질 키나제 억제제로서 치환된 피롤로 [2, 3-b] 피리딘 및 피라졸로 [3,4-b] 피리딘 유도체
JP6927548B2 (ja) ある種のタンパク質キナーゼ阻害剤
JP6966044B2 (ja) タンパク質キナーゼ阻害剤としての置換されているピロロ［２，３−ｄ］ピリダジン−４−オン及びピラゾロ［３，４−ｄ］ピリダジン−４−オン
RU2778294C2 (ru) Макроциклические соединения как ингибиторы киназ trk
TW202017927A (zh) 作爲RET激酶抑制劑的取代的[1,2,4]三唑[1,5-a]吡啶化合物
RU2781618C2 (ru) ЗАМЕЩЕННЫЕ (2-АЗАБИЦИКЛО[3.1.0]ГЕКСАН-2-ИЛ)ПИРАЗОЛО[1.5-a]ПИРИМИДИНОВЫЕ И ИМИДАЗО[1.2-b]ПИРИДАЗИНОВЫЕ СОЕДИНЕНИЯ КАК ИНГИБИТОРЫ КИНАЗ TRK
WO2021047584A1 (fr) Composés de (2-azabicyclo [3.1.0] hexan-2-yl) pyrazolo [1, 5-a] pyrimidine et imidazo [1, 2-b] pyridazine substitués utilisés comme inhibiteurs de kinases trk
TW202028199A (zh) 作為蛋白激酶抑制劑的萘啶酮和吡啶基嘧啶酮類化合物

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20201110

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220104

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20221222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230131

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230425

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230801